ClinicalTrials.gg
CompletedNCT06285838Updated Feb 29, 2024

Impact of Measures Taken to Contain COVID-19 on Hospital Surgical Care Services and Clinical Outcomes

An observational study in COVID-19, sponsored by Singapore Health Services. Completed at 1 site in Singapore. Open to participants aged 21 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-02-29.

Sponsored by Singapore Health Services · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
11,000
Ages
21 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies in COVID-19 with a site in Singapore — none open to participants now, 1 under way, none of them phase 3. COVID-19 · Singapore.

Enrollment
Largest of 17
11,000 · median 670
Started
2020
with 28 others
Observational
17 of 51
none open now
Registered
49th of 51
by date

Among the 51 studies in COVID-19 with a site in Singapore, this one has the largest enrollment of the 17 observational ones that give a count, is one of 29 that started in 2020, is one of 17 observational ones, and was the 49th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

None of the 51 studies in COVID-19 with a site in Singapore is open now. The open studies under COVID-19, anywhere →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 21 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 51 studies in COVID-19 with a site in Singapore as a file.
02

Study summary

Swift and decisive actions on the part of healthcare and hospital authorities are required to effectively contain the current COVID-19 pandemic. These measures firstly allow personnel and facilities leeway to provide surge capabilities to meet anticipated increased demands on the healthcare service. In addition, by deferring none urgent hospital visits, admissions and investigations, such measures support social distancing and aid attempts to control disease transmission. Deferring perceived non-urgent patient services may however lead to unintended delayed diagnoses and exacerbation of current patient conditions and lead to increased emergency admissions and surgeries.

A policy decision was made that essential surgical services pertaining to cancer and urgent cardiovascular surgery were allowed but that surgeons had the option to postpone what is assessed to be less urgent cases. Increasingly patients also postpone their surgeries or visits because of anxieties over the developing situation. Elective surgical services at the Outram Campus were thus significantly reduced from January 2020 as part of the measures to contain the COVID-19 outbreak.

The surgical philosophy during this period was that a judicious policy that allowed surgeons to proceed with surgery deemed critical but to postpone those deemed less so will at the system level, avoid poor outcomes for patients who required surgery and yet successfully re-allocate resources required to address the unfolding pandemic.

Read the detailed description

Cohort of patients who were treated will be analysed via retrospective medical records review. These patients are classified according to the institution, type of surgical procedures, the medical condition and the dates of surgical treatment. The study will be compared across four time periods as listed:

-1Jan-31Dec2020 -1Jan-31Dec2019 -1Jan-31Dec2018 -1Jan-31Dec2017

The study focus on surgical indices for selected high-volume cancer and non-cancer diagnoses over the period 1st January 2020 to 31 December 2020 and compare them with similar indices across the same period of time in the preceding 3 years in particular, for the following surgical procedures:

  1. Surgeries for the following cancer diagnoses:

    1. breast cancer, [XIV- N60, no malignancy], [Malignant, II Neoplasms- C50], colorectal cancer, [C18, 19, 20],
    2. hepatocellular carcinoma, [C22]
  2. Selected non-cancer surgeries: a. Cholecystectomy b. Abdominal hernia repair
03

Conditions studied

  • COVID-19

Browse trials for

Keywords

  • impact of measures
  • hospital surgical care services
04

Who can participate

Ages eligible
21 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients coming to SGH for surgeries

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who had the following surgeries during the period 01 Jan 2017 to 31 December 2020.

From the identified surgical procedure type as shown Surgeries for the following cancer-related procedures.

  1. Breast Cancer
  2. Colon Cancer
  3. Liver
  4. Rectum

Selected non-cancer surgeries.

  1. Abdominal Wall
  2. Gall bladder

Patients from SGH and its releated institute NCC Only local Singapore citizens

Exclusion criteria

Exclusion Criteria:

No exclusion criteria

-

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
11,000 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Impact of measures taken to contain COVID-19 on hospital surgical care services and clinical outcomes

    Study seeks to assess the effect of the measures taken to contain COVID 19 on patients who need surgical services measured by patient outcomes, such as, length of hospital stay (LOS), ICU stay, APACHE score, stage of cancer at surgery.

    Time frame: 4 years

07

Study locations

1 site
  • Singapore Health Services Pte ltd
    Singapore, 169856, Singapore
08

References and documents

Publications

  • Mazingi D, Navarro S, Bobel MC, Dube A, Mbanje C, Lavy C. Exploring the Impact of COVID-19 on Progress Towards Achieving Global Surgery Goals. World J Surg. 2020 Aug;44(8):2451-2457. doi: 10.1007/s00268-020-05627-7. PubMed 32488665 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2020 to primary completion in Nov 2023, 40 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2024
First posted
Feb 29, 2024
StartActual
Jul 17, 2020
Primary completionActual
Nov 30, 2023
CompletionActual
Jan 20, 2024
Last update
Feb 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06285838
Lead sponsor
Singapore Health Services
Responsible party
Sean Shao Wei Lam (Deputy Director, Singapore Health Services) — Principal investigator
First posted
Feb 29, 2024
Start date
Jul 17, 2020
Primary completion
Nov 30, 2023
Completion
Jan 20, 2024
Last update
Feb 29, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion